Elite in Small Lymphocytic Lymphoma (SLL)

Dr. Shuo Ma

Hematology | Oncology
Northwestern Medical Group
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
Offers Telehealth
32 Years of Experience
Elite in Small Lymphocytic Lymphoma (SLL)
Northwestern Medical Group
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Shuo Ma is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Ma has been practicing medicine for over 32 years and is rated as an Elite provider by MediFind in the treatment of Small Lymphocytic Lymphoma (SLL). Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 83 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 40 articles and participated in 4 clinical trials in the study of Small Lymphocytic Lymphoma (SLL).

Graduate Institution
Beijing Medical University, 1994.0
Residency
Ascension Illinois/St Joseph (Chicago)
Specialties
Hematology
Oncology
Licenses
Internal Medicine in IL
Board Certifications
American Board Of Internal Medicine - Hematology (Certified)
Fellowships
McGaw Medical Center of Northwestern University
Hospital Affiliations
Northwestern Memorial Hospital
Northwestern Lake Forest Hospital
Palos Community Hospital
Northwestern Medicine Delnor Community Hospital
Northwestern Medicine Central Dupage Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

675 N St Clair St Ste 21-100, Galter Pavilion, Chicago, IL 60611
Call: 866-587-4322

Additional Areas of Focus

Dr. Ma has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)
A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)
Enrollment Status: Completed
Publish Date: July 11, 2025
Intervention Type: Drug
Study Drug: Parsaclisib
Study Phase: Phase 2
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Enrollment Status: Active_not_recruiting
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Bendamustine, Rituximab, Venetoclax
Study Phase: Phase 3
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
Enrollment Status: Completed
Publish Date: January 23, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Obinutuzumab
Study Phase: Phase 2
Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma
Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma
Enrollment Status: Unknown
Publish Date: June 02, 2023
Intervention Type: Procedure, Drug, Radiation, Other, Biological
Study Drugs: Dacarbazine, Doxorubicin, Pembrolizumab, Vinblastine, 18F-Fludeoxyglucose
Study Phase: Phase 2
Phase II Trial of Pembrolizumab in Combination With ICE Salvage Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma
Phase II Trial of Pembrolizumab in Combination With ICE Salvage Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma
Enrollment Status: Unknown
Publish Date: June 02, 2023
Intervention Type: Drug, Other, Biological
Study Drugs: Carboplatin, Etoposide, Ifosfamide, Pembrolizumab
Study Phase: Phase 2
A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas
A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas
Enrollment Status: Terminated
Publish Date: September 01, 2021
Intervention Type: Other, Biological, Drug
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

83 Total Publications

MBE Growth of High-Quality HgCdSe for Infrared Detector Applications.
MBE Growth of High-Quality HgCdSe for Infrared Detector Applications.
Journal: Materials (Basel, Switzerland)
Published: June 12, 2025
View All 83 Publications
Similar Doctors
Distinguished in Small Lymphocytic Lymphoma (SLL)
Dr. Jane N. Winter
Hematology | Oncology
Distinguished in Small Lymphocytic Lymphoma (SLL)
Dr. Jane N. Winter
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (0.1 miles away)
866-587-4322
Experience:
49+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jane Winter is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Winter has been practicing medicine for over 49 years and is rated as an Elite provider by MediFind in the treatment of Small Lymphocytic Lymphoma (SLL). Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Bone Marrow Transplant.

Leo I. Gordon
Distinguished in Small Lymphocytic Lymphoma (SLL)
Dr. Leo I. Gordon
Hematology | Oncology
Distinguished in Small Lymphocytic Lymphoma (SLL)
Dr. Leo I. Gordon
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (0.1 miles away)
866-587-4322
Experience:
53+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Leo Gordon is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Gordon has been practicing medicine for over 53 years and is rated as an Elite provider by MediFind in the treatment of Small Lymphocytic Lymphoma (SLL). His top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Distinguished in Small Lymphocytic Lymphoma (SLL)
Dr. Lynne Kaminer
Hematology
Distinguished in Small Lymphocytic Lymphoma (SLL)
Dr. Lynne Kaminer
Hematology

Endeavor Health Medical Group

2650 Ridge Ave, 
Evanston, IL 
 (12.3 miles away)
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lynne Kaminer is a Hematologist in Evanston, Illinois. Dr. Kaminer has been practicing medicine for over 44 years and is rated as a Distinguished provider by MediFind in the treatment of Small Lymphocytic Lymphoma (SLL). Her top areas of expertise are Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Bone Marrow Aspiration, and Bone Marrow Transplant.

VIEW MORE SMALL LYMPHOCYTIC LYMPHOMA (SLL) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ma's expertise for a condition
ConditionClose
  • Elite
  • Chronic B-Cell Leukemia (CBCL)
    Dr. Ma is
    Elite
    . Learn about Chronic B-Cell Leukemia (CBCL).
    See more Chronic B-Cell Leukemia (CBCL) experts
  • Chronic Lymphocytic Leukemia (CLL)
    Dr. Ma is
    Elite
    . Learn about Chronic Lymphocytic Leukemia (CLL).
    See more Chronic Lymphocytic Leukemia (CLL) experts
  • Small Lymphocytic Lymphoma (SLL)
    Dr. Ma is
    Elite
    . Learn about Small Lymphocytic Lymphoma (SLL).
    See more Small Lymphocytic Lymphoma (SLL) experts
  • Distinguished
  • B-Cell Lymphoma
    Dr. Ma is
    Distinguished
    . Learn about B-Cell Lymphoma.
    See more B-Cell Lymphoma experts
  • Follicular Lymphoma
    Dr. Ma is
    Distinguished
    . Learn about Follicular Lymphoma.
    See more Follicular Lymphoma experts
  • Leukemia
    Dr. Ma is
    Distinguished
    . Learn about Leukemia.
    See more Leukemia experts
  • Mantle Cell Lymphoma (MCL)
    Dr. Ma is
    Distinguished
    . Learn about Mantle Cell Lymphoma (MCL).
    See more Mantle Cell Lymphoma (MCL) experts
  • Marginal Zone Lymphoma (MZL)
    Dr. Ma is
    Distinguished
    . Learn about Marginal Zone Lymphoma (MZL).
    See more Marginal Zone Lymphoma (MZL) experts
  • Non-Hodgkin Lymphoma
    Dr. Ma is
    Distinguished
    . Learn about Non-Hodgkin Lymphoma.
    See more Non-Hodgkin Lymphoma experts
View All 9 Distinguished Conditions
  • Advanced
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Ma is
    Advanced
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Myeloid Leukemia (AML)
    Dr. Ma is
    Advanced
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Autoimmune Hemolytic Anemia
    Dr. Ma is
    Advanced
    . Learn about Autoimmune Hemolytic Anemia.
    See more Autoimmune Hemolytic Anemia experts
  • Bone Marrow Aspiration
    Dr. Ma is
    Advanced
    . Learn about Bone Marrow Aspiration.
    See more Bone Marrow Aspiration experts
  • Chronic Familial Neutropenia
    Dr. Ma is
    Advanced
    . Learn about Chronic Familial Neutropenia.
    See more Chronic Familial Neutropenia experts
  • Diffuse Large B-Cell Lymphoma (DLBCL)
    Dr. Ma is
    Advanced
    . Learn about Diffuse Large B-Cell Lymphoma (DLBCL).
    See more Diffuse Large B-Cell Lymphoma (DLBCL) experts
View All 11 Advanced Conditions
  • Experienced
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Ma is
    Experienced
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Ma is
    Experienced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Adult Immune Thrombocytopenia
    Dr. Ma is
    Experienced
    . Learn about Adult Immune Thrombocytopenia.
    See more Adult Immune Thrombocytopenia experts
  • Adult Soft Tissue Sarcoma
    Dr. Ma is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Agranulocytosis
    Dr. Ma is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Ma is
    Experienced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
View All 78 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.